Sema Yildirim

Dr. Sema Yildirim

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2021 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
ÖBÖmer Faruk Beşer
Ömer Faruk Beşer
FCFugen Cullu Cokugras
Fugen Cullu Cokugras
GDGuzide Dogan
Guzide Dogan
ÖAÖzlem Akgün
Özlem Akgün
MEMurat Elevli
Murat Elevli
Yvan VandenplasYvan Vandenplas
Yvan Vandenplas

1 May 2025 in European Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
MSMukaddes kılıç sağlam
Mukaddes kılıç sağlam
SYSema Yildirim
Sema Yildirim
MEMüferet Ergüven
Müferet Ergüven
MSMehmet Ali SUNGUR
Mehmet Ali SUNGUR
Immunoglobulin A (IgA) vasculitis is the most common systemic vasculitis in childhood, primarily affecting the skin, gastrointestinal system (GIS), joints, and kidneys. This study aimed to evaluate the clinical and laboratory characteristics of mild and severe GIS involvement in pediatric patients with IgA vasculitis and to investigate its association with renal involvement. A retrospective review was conducted on 794 pediatric patients diagnosed with IgA vasculitis between 1997 and 2024. Demographic data, clinical findings, and laboratory parameters were collected from patient records. GIS involvement was classified as mild (abdominal pain, vomiting, or occult blood in stool) or severe (melena, hematochezia, or intussusception). Renal involvement was defined based on hematuria, proteinuria, hypertension, or renal insufficiency. Among 794 patients, 430 (54.2%) were male, with a mean age at diagnosis of 7.8 ± 3.3 years. GIS involvement was observed in 422 (53.1%) patients, of whom 333 (78.9%) had mild GIS involvement and 89 (21.1%) had severe GIS involvement. Renal involvement was detected in 171 (21.5%) patients, and was more frequent in those with GIS involvement (26.3% vs. 16.1%, p = 0.001). GIS (55.6% (n = 306) vs. 47.1% (n = 115)) and renal (24.5% (n = 134) vs. 15.2% (n = 37)) involvement were more common in patients aged > 5 years than in patients ≤ 5 years (p = 0.027, p = 0.004, respectively). GIS involvement was significantly associated with leukocytosis (p < 0.001) and elevated C-reactive protein (CRP) (p = 0.018), but these parameters did not correlate with renal involvement. Patients with positive fecal occult blood tests had a significantly higher risk of renal involvement (p < 0.001). However, there was no significant difference in renal involvement between patients with mild and severe GIS involvement (p = 0.082). Conclusion: GIS involvement, older age (> 5 years), and the presence of occult blood in stool were associated with a higher likelihood of renal involvement in pediatric IgA vasculitis. However, the severity of GIS involvement did not correlate with renal involvement, suggesting that renal pathology may be influenced by independent mechanisms rather than the severity of GIS symptoms. What is Known:• Older age, persistent palpable purpura, abdominal pain, GIS involvement, recurrent disease episodes are risk factors for renal involvement in IgA vasculitis. What is New:• GIS involvement, fecal occult blood positivity, and age over five years were significantly associated with renal involvement in pediatric IgA vasculitis. However, the severity of GIS involvement did not predict the presence or severity of renal involvement.


21 February 2026 in Pediatric Research
Verified
Journal Article
Open access
EEElif Selcen Yabanci Erten
Elif Selcen Yabanci Erten
LKLutfiye Koru
Lutfiye Koru
FKFeray Kaya
Feray Kaya
EKElif Kucuk
Elif Kucuk
ZAZelal Aydin
Zelal Aydin
FHFatih Haslak
Fatih Haslak
Background: Data on prophylaxis in children with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) are limited for probiotics. We aimed to evaluate clinical responses of probiotic and colchicine. Methods: We included PFAPA patients receiving colchicine or probiotic (Lactobacillus plantarum HEAL9 (5×10 8 cfu/tablet), Lactobacillus paracasei 8700:2 (5 × 10 8 cfu/tablet) and a vitamin mixture (0.75 μg/tablet vitamin D3, 0.38 μg/tablet, vitamin B12, 30 μg/tablet folic acid)) for ≥3 months. Disease activity was assessed using Auto-Inflammatory Disease Activity Index (AIDAI). Monthly AIDAI scores from 3-month periods before and after prophylaxis were compared retrospectively. Early clinical response was defined as AIDAI score change from the month before to after prophylaxis. The time to first attack was compared. Results: The study included 130 patients (colchicine: n  = 97; probiotics: n = 33). Significant early clinical response occurred in both groups, with median AIDAI scores decreasing from the month before to after prophylaxis (colchicine: p < 0.001; probiotics: p < 0.001). Time to first attack was longer in the colchicine group than probiotic group ( p = 0.048). Conclusion: Colchicine and probiotics showed similar short-term improvement in PFAPA activity. However, differences exist in time to first attack and adverse effects and should be discussed with families when selecting prophylaxis. Impact: This study provides one of the first evaluations of clinical responses to colchicine and probiotic prophylaxis in children with PFAPA syndrome using objective disease activity scoring. By demonstrating clinical improvements in both groups, the study contributes to the growing body of evidence supporting probiotic use. The identification of gastrointestinal symptoms as a factor affecting colchicine response may contribute to a more personalized treatment approach. These findings contribute valuable data to the limited literature on PFAPA prophylaxis and support shared decision-making in clinical practice.

1 January 2024 in Asthma Allergy Immunology
Verified
Journal Article
Closed access
SYSema Yildirim
Sema Yildirim
MYMehtap Yazicioglu
Mehtap Yazicioglu
SCSukran Ciftci
Sukran Ciftci

22 January 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SYSema Yildirim
Sema Yildirim
HBHayrunnisa Bekis Bozkurt
Hayrunnisa Bekis Bozkurt
MEMuferet Erguven
Muferet Erguven
Background/Objectives: Studies have shown that some mutations, especially M694V, are correlated with renal RI and/or AA. There are limited data about rare mutations on severity of the disease and RI. Today, evaluating genotype–phenotype correlations in rare mutations is important to better understand FMF. We aimed to evaluate clinical, demographic and genetic changes and genotype–phenotype correlations in pediatric patients with FMF over thirty years as well as the importance of the rare mutations. Methods: A total of 2765 pediatric patients with FMF were included in this study. Genetic results were firstly divided into ten groups including rare mutations. Rare mutations were seen in 2% of all patients and divided into eight groups. Results: There was a significant increase in compound heterozygous mutations, E148Q het/hom, R202Q het/hom, complex mutations and rare mutations in the last decade. RI wo AA was 5.8% and AA was 1% in the patients with rare mutations. While M694V and compound het with M694V were positively correlated with severe PRAS, E148Q and V726A were negatively correlated with severe PRAS (p < 0.05, R = 0.137, R = −0.077, R= −0.05, respectively). Although K695R mutation was negatively correlated with severe PRAS (p < 0.05, R = −0.04), the rate of RI was 20%. Although the rare mutation R761H was negatively correlated with severe PRAS (p < 0.05, R = −0.051), the colchicine resistance rate was 8.3%. Conclusions: It may be misleading for clinicians that mutations which have increased in frequency over the years are clinically mild. RI and AA rates in rare mutations are not less than the related rates in common mutations.